Colombia takes on cancer: first CAR-T trial for relapsed blood cancers
NCT ID NCT07412405
First seen Feb 25, 2026 · Last updated Apr 30, 2026 · Updated 7 times
Summary
This study aims to bring a cutting-edge cancer treatment, CAR-T cell therapy, to Colombia for the first time. It will test the safety of a locally produced CAR-T product in 12 adults with certain relapsed or treatment-resistant blood cancers, such as lymphoma and leukemia. The study also focuses on building the necessary infrastructure and partnerships to make this therapy available in the country.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA (FL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.